The purpose of this study is to determine if 0.5% Ivermectin Cream is a safe and effective treatment for head lice infestations.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
371
Up to 4 ounces of 0.5% Ivermectin Cream applied to hair and scalp on day 1.
up to 4 ounces of topical vehicle control to head and scalp on day 1.
Arkansas Pediatric Clinic
Little Rock, Arkansas, United States
Lice Cleanique, LLC
Delray Beach, Florida, United States
Hill Top Research
St. Petersburg, Florida, United States
Lovelace Scientific Resources, Inc.
Albuquerque, New Mexico, United States
Percentage of Index Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 15 Post-treatment With Either Ivermectin or Placebo (Vehicle Control)
Treatment success, defined as absence of live lice, was assessed in index subjects, defined as the youngest person within each household who had at least 3 live lice present at Screening (Day 1). Treatment success was assessed by last observation carried forward (LOCF) imputation and treatment failure imputation.
Time frame: Day 2 up to Day 15 post-application
Percentage of All Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 15 Post-treatment With Either Ivermectin or Placebo (Vehicle Control)
Treatment success, defined as absence of live lice, was assessed in all subjects. Treatment success was assessed by last observation carried forward (LOCF) imputation and treatment failure imputation.
Time frame: Day 2 up to Day 15 post-application
Number of Participants Reporting Treatment-Emergent Adverse Events Post-treatment With Either Ivermectin or Placebo (Vehicle Control)
Adverse events were defined and classified as follows: 'Mild' - Awareness of signs or symptoms, but easily tolerated; 'Moderate' - Discomfort to a degree that adverse event/adverse drug reaction causes interference with normal daily life activities and/or requires medication; 'Severe' - Incapacity with regard to work or usual daily life activities. Requires medical attention/intervention.
Time frame: Day 2 up to Day 15 post-application
Summary of the Reported Skin/Scalp Irritation Before and Post-treatment With Either Ivermectin or Placebo (Vehicle Control)
Severe skin/scalp irritations were defined as follows: Severe Pruritus - Nearly constant, frequent scratching, very bothersome; Severe Erythema - large areas of the scalp are red; Severe Excoriation - Widespread breaking of the skin involving most of the scalp; Severe Pyoderma - Lesions with crusting or other evidence of infection, involving most of the scalp.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Haywood Pediatric and Adolescent Medicine Group, PA
Clyde, North Carolina, United States
LSRN
Nashville, Tennessee, United States
Northeast Houston Pediatric Clinic
Houston, Texas, United States
Time frame: Day 2 up to Day 15 post-application